ArticleLipids in health and disease2017
Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults.
Article in Lipids in health and disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- The Correlation Between Serum Uric Acid and Metabolic Dysfunction-Associated Fatty Liver Disease: An Updated Systematic Review and Meta-Analysis.Journal of general internal medicine · 2026Pooled it
- Epidemiology of lean/non-obese nonalcoholic fatty liver disease in China: A systematic review and meta-analysis.Saudi medical journal · 2023Pooled it
- Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials.Clinical rheumatology · 2020Pooled it
- Citrus Bergamia and Cynara Cardunculus Reduce Serum Uric Acid in Individuals with Non-Alcoholic Fatty Liver Disease.Medicina (Kaunas, Lithuania) · 2022Trial
- Association between serum uric acid and non-alcoholic fatty liver disease (NAFLD): an observational cross-sectional study in an Egyptian outpatient cohort.BMC gastroenterology · 2026Observational
- Associations between serum uric acid related ratios and the onset of metabolic dysfunction associated steatotic liver disease.Scientific reports · 2025Article
- Combined effect of fasting blood glucose and serum uric acid on nonalcoholic fatty liver disease.Lipids in health and disease · 2025Article
- Gender difference in the association between serum uric acid and metabolic dysfunction-associated steatotic liver disease in patients with newly diagnosed type 2 diabetes.BMC gastroenterology · 2025Article
- The role of Triglyceride Glucose-Waist Circumference (TyG_WC) in predicting metabolic dysfunction-associated steatotic liver disease among individuals with hyperuricemia.BMC gastroenterology · 2025Article
- Serum uric acid as a biomarker for metabolic dysfunction-associated steatotic liver disease: insights from ultrasound elastography in a Chinese cohort.BMC gastroenterology · 2025Article
- Predictive value of serum uric acid to high-density lipoprotein cholesterol ratio for MAFLD in non-obese type 2 diabetes patients based on nomogram.Frontiers in endocrinology · 2025Article
- Could serum uric acid levels be a biomarker for metabolic dysfunction-associated steatotic liver disease?Gastroenterology and hepatology from bed to bench · 2025Article
- A nomogram for predicting metabolic-associated fatty liver disease in non-obese newly diagnosed type 2 diabetes patients.Frontiers in endocrinology · 2025Article
- Association between the ratio of serum uric acid to high-density lipoprotein cholesterol and liver fat content: evidence from a Chinese health examination dataset.Scientific reports · 2024Article
- A machine learning-based predictive model discriminates nonalcoholic steatohepatitis from nonalcoholic fatty liver disease.Heliyon · 2024Article
- Serum uric acid and nonalcoholic fatty liver disease.Frontiers in endocrinology · 2024Review
- The risk of nonalcoholic fatty liver disease in gout patients with frequent flares: a retrospective cohort study.Clinical rheumatology · 2023Article
- Hyperuricemia as an effect modifier of the association between metabolic phenotypes and nonalcoholic fatty liver disease in Chinese population.Journal of translational medicine · 2023Article
- Clinical characterization and proteomic profiling of lean nonalcoholic fatty liver disease.Frontiers in endocrinology · 2023Article
- Metabolic characteristics of non-obese and obese metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus and its association with diabetic peripheral neuropathy and diabetic retinopathy.Frontiers in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies found elevated serum uric acid (SUA) was associated with the development or progression of non-alcoholic fatty liver disease (NAFLD) in general population; in this study we aim to investigate the association of SUA and the severity of NAFLD based on grade of fatty liver on ultrasonography in non-obese subjects.
methodsData were obtained from subjects via routine physical examinations in the Public Health Center of our hospital between 2011 and 2014. The data included completed anthropometry and blood biochemical indicators and the results of abdominal ultrasound. The diagnosis of NAFLD was according to the clinical diagnosis of the Guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease in 2008.
resultsIn total, 95,924 subjects were analyzed in this study. The prevalence rate of lean-NAFLD was 8.16%, among which 7.58% had mild steatosis, and 0.58% had moderate and severe steatosis. The prevalence of fatty liver was increased progressively with SUA. Among which the prevalence of mild fatty liver from Q1 to Q4 were 10.33%, 18.39%, 23.11% and 25.93%; the prevalence of moderate and severe fatty liver from Q1 to Q4 were 1.06%, 2.82%, 5.05% and 7.27%. Lean-subjects with hyperuricemia had an OR of 1.718 (95% CI 1.622-1.820) to have NAFLD, after adjusted for other metabolic disorders. The area under curve (AUC) for detecting mild fatty liver based on SUA was 0.70; and the AUC for detecting moderate and severe fatty liver based on SUA was 0.78.
conclusionsOur data showed positive associations between elevated SUA levels and lean-NAFLD risk in the inland Chinese adults, independent of other metabolic factors. Our study also suggests that SUA could be considered as a simple and non-invasive method to follow up patients with lean-NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.